A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile
Public ClinicalTrials.gov record NCT02702388. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-Blind Phase 2 Trial of Lenvatinib (E7080) in Subjects With 131I-Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily Will Provide Comparable Efficacy to a 24-mg Starting Dose, But Have a Better Safety Profile
Study identification
- NCT ID
- NCT02702388
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Eisai Inc.
- Industry
- Enrollment
- 241 participants
Conditions and interventions
Conditions
Interventions
- Lenvatinib Drug
- Lenvatinib matching placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 7, 2017
- Primary completion
- Dec 11, 2019
- Completion
- Sep 9, 2020
- Last update posted
- Nov 23, 2021
2017 – 2020
United States locations
- U.S. sites
- 16
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Facility#1 | La Jolla | California | 92093 | — |
| Facility #1 | San Diego | California | 92307 | — |
| Facility #1 | Torrance | California | 90502 | — |
| Facility #1 | Washington D.C. | District of Columbia | 20010 | — |
| Facility #1 | Boston | Massachusetts | 02114 | — |
| Facility #2 | Boston | Massachusetts | 02115 | — |
| Facility #1 | Ann Arbor | Michigan | 48109 | — |
| Facility #1 | Detroit | Michigan | 48201 | — |
| Facility#2 | Morristown | New Jersey | 07962 | — |
| Facility#1 | Summit | New Jersey | 07902 | — |
| Facility #1 | The Bronx | New York | 10461 | — |
| Facility #1 | Columbus | Ohio | 43210 | — |
| Facility #1 | Portland | Oregon | 97239 | — |
| Facility #2 | Philadelphia | Pennsylvania | 19104 | — |
| Facility #1 | Philadelphia | Pennsylvania | 19111 | — |
| Facility #1 | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 85 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02702388, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 23, 2021 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02702388 live on ClinicalTrials.gov.